Figure 1.

Combination of osimertinib plus DHA, R428, TPX-0005, or BML-258 in HNSCC cell lines. The FaDu (A) and CAL27 (B) HNSCC cell lines were assayed using MTT assay. In the upper panel of A and B, the shifting of dose-response curves of osimertinib in the presence (black triangle) or absence of DHA, R428, TPX-0005, and BML-258 (black circle) is presented. Combination index (CI) plots showing anticancer activity of osimertinib combined with DHA, R428, TPX-0005, and BML-258 in different sequences in the FaDu and CAL27 cell lines are shown in the lower panel of A and B. CI values were plotted as a function of fractional growth inhibition (Fa). CI <1, =1, and >1 suggest synergism, additivity, and antagonism, respectively. The results represent the means of at least three independent experiments. Data are presented as the means ± standard deviation. DHA, dihydroartemisinin; HNSCC, head and neck squamous cell carcinoma.